Synthetic Biology Market Size

Synthetic Biology Market size was valued at USD 14.18 Billion in 2023 and is poised to grow from USD 17.8 Billion in 2024 to USD 109.52 Billion by 2032, growing at a CAGR of 25.5% during the forecast period (2025-2032).

The synthetic biology market providers need to focus on maximizing their business scope by reaching into new markets and developing synthetic biology for different industrial and personal uses. Raising new capital to fund their R&D and business expansion efforts will be essential for new synthetic biology companies going forward. The development of custom robots for specific applications across different industry verticals will also help companies expand their sales potential in the future. 'Genentech Inc. (U.S.)  ', 'Sorenson Genomics, LLC (U.S.)  ', 'Abbott Molecular (U.S.)  ', 'Bayer Diagnostics (U.S.)  ', 'Genomic Health (U.S.)  ', 'Thermo Fisher Scientific Inc. (US)  ', 'Merck KGaA (Germany)  ', 'Agilent Technologies (US)  ', 'Novozymes (Denmark)  ', 'Ginkgo Bioworks (US)  ', 'Amyris (US)  ', 'Precigen, Inc. (US)  ', 'GenScript (China)  ', 'Twist Bioscience (US)  ', 'Synthetic Genomics (US)  ', 'Codexis, Inc. (US)  ', 'Synthego (US)  ', 'Creative Enzymes (US)  ', 'Eurofins Scientific (Luxembourg)  ', 'Bota Biosciences Inc. (China)  ', 'Creative Biogene (US)  ', 'Enbiotix, Inc. (US)  ', 'Illumina, Inc. (US)  ', 'New England Biolabs (US)  ', 'Pareto Bio, Inc. (US) '

Synthetic biology is improving the emergence of novel therapies, diagnostics, and vaccines, impacting the surging use in healthcare and pharmaceutical sectors. Furthermore, the said technology is used in the development of genetically tailored crops with improved resistance to diseases and pests, which aids agriculture productivity and food security. These factors are impressively helping the growth of the synthetic biology market. 

Engineered gene’s expression is dictated by complex & dynamic epigenetics and DNA sequence. This over-activates synthetic constructs, resulting in inconsistent outcomes. Owing to this feature, the newbies in the market are bringing innovations in epigenetics technologies to navigate and handle these intricacies. 

Geographically, the synthetic biology market is leading in North America owing to several factors like robust research and development architecture. Mainly, Canada and the United States holds a strong infrastructure for research and development. This comprises top-class universities, research institutes, and biotech companies that fuel inventions and advances in the domain of synthetic biology. Moreover, growing funding and heavy investments in synthetic biology and biotechnology from both public and private sectors aid better research and development of technologies in the region. The leading vendors operating in North America include Thermo Fisher Scientific, Agilent Technologies, Ginkgo Bioworks, and Amyris, Inc. among others.